A higher diameter and a faster enlargement rate of the body’s main pulmonary artery — dubbed the MPA, it carries oxygen-poor blood out of the heart toward the lungs — are independent predictors of poor outcomes among people with pulmonary arterial hypertension (PAH), a new study reports. In predicting…
News
A higher diameter ratio on CT scans between the right ventricle and left ventricle, which are the heart’s lower chambers, independently predicts major adverse cardiovascular events in people with pulmonary hypertension (PH), a study reports. “In our study, the [right ventricle/left ventricle] ratio not only well reflected PH severity,…
Researchers in the U.S. have developed a tool to help predict mortality risk in people with chronic lung disease and pulmonary hypertension (PH). The tool, PVD-B65, accounts for risk factors related to both conditions, including age, lung disease type, PH severity, exercise capacity, and blood levels of a heart…
Corsair Pharma successfully completed preclinical studies testing its skin patch delivery system for treprostinil as a treatment for pulmonary arterial hypertension (PAH), and is now planning to launch a Phase 1 clinical trial in the next few months. That’s according to new updates from the U.S.-based company, which…
People with coarctation of aorta, or COA — a condition marked by narrowing where the body’s largest blood vessel connects to the heart — are at high risk of developing pulmonary hypertension (PH), and this risk increases as time goes on, a study showed. The data also showed that…
Boosting the production of a protein called myotubularin-related protein 7 (MTMR7) reversed signs of pulmonary arterial hypertension (PAH) in a mouse model of the disease, a study shows. MTMR7 suppresses the excess growth and migration of cells lining the arteries, which contribute to the narrowing of these blood vessels…
The National Organization for Rare Disorders (NORD) is seeking participants for its survey-based study Living Rare, which aims to better understand the real-world lived experiences of people in the U.S. with rare diseases. Living Rare, the first large-scale study of its kind in the U.S., seeks to capture the…
Insulin resistance or IR — a reduced response of body tissues to insulin, a hormone that regulates blood sugar levels — was found to correlate with disease severity in people with chronic thromboembolic pulmonary hypertension (CTEPH), according to a new study from researchers in China. Further, the team determined that…
Tenax Therapeutics said it will extend its Phase 3 clinical development of an oral form of levosimendan for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The company last year received $100 million in funding to help it complete an ongoing Phase 3 LEVEL trial…
Inhibiting an enzyme known as Aurora kinase B (AURKB) significantly improves multiple measures of blood flow in rat models of pulmonary arterial hypertension (PAH), a study suggests. AURKB blockade worked by suppressing the excessive growth of blood vessel muscle cells, which contributes to the narrowing of pulmonary arteries that…
Winrevair (sotatercept) is generally safe and effective for people with pulmonary arterial hypertension (PAH) when given in addition to their standard of care treatment, a pooled analysis of two clinical trials shows. Along with other benefits, the clinical studies — the Phase 2 PULSAR trial (NCT03496207) and…
Celastrol, a herbal compound used in traditional Chinese medicine, may help prevent pulmonary hypertension associated with bronchopulmonary dysplasia (BPD-PH) by reducing inflammation and protecting lung tissue from damage, a study in rats and lab-grown cells suggests. While these preclinical findings are promising, the compound is still experimental and more…
